Truist Financial Has Lowered Expectations for Cabot (NYSE:CBT) Stock Price

Key Points

• Truist Financial cut its Cabot price target from $100 to $95 but maintained a Buy rating; the new target implies 26.5% upside from the previous close.
• Analyst opinion is mixed: MarketBeat reports a consensus Hold rating and an average price target of $86.80, with two Buy, four Hold, and one Sell ratings.
• Cabot beat quarterly estimates, reporting EPS of $1.61 versus $1.55 expected and revenue up 12.2% year over year to $1.01 billion. However, fiscal 2027 adjusted EPS guidance of $6.15–$6.75 came in below the $7.03 analyst consensus.

Cabot (NYSE:CBT - Get Free Report) had its price objective lowered by investment analysts at Truist Financial from $100.00 to $95.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the specialty chemicals company's stock. Truist Financial's target price suggests a potential upside of 26.50% from the company's previous close.

Other research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Cabot from a "hold" rating to a "buy" rating in a research report on Sunday, October 11th. JPMorgan Chase & Co. raised their target price on Cabot from $70.00 to $78.00 and gave the company an "underweight" rating in a report on Friday, August 7th. UBS Group decreased their price target on Cabot from $92.00 to $86.00 and set a "neutral" rating on the stock in a research note on Monday, October 5th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Cabot in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $86.80.

Cabot Stock Performance

NYSE CBT traded up $3.10 during trading on Wednesday, reaching $75.10. The company's stock had a trading volume of 122,028 shares, compared to its average volume of 455,000. The firm has a 50 day moving average price of $77.55 and a 200 day moving average price of $79.52. Cabot has a 12 month low of $58.33 and a 12 month high of $94.53. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 8.91 and a beta of 0.83. The company has a current ratio of 1.47, a quick ratio of 0.97 and a debt-to-equity ratio of 0.48.

Cabot (NYSE:CBT - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $1.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.55 by $0.06. Cabot had a return on equity of 19.79% and a net margin of 5.69%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $927.29 million. During the same quarter in the prior year, the business posted $1.70 earnings per share. The firm's quarterly revenue was up 12.2% compared to the same quarter last year. As a group, equities analysts anticipate that Cabot will post 7.08 EPS for the current fiscal year.

Insider Activity at Cabot

In other Cabot news, CEO Sean Keohane sold 134,895 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $85.00, for a total transaction of $11,466,075.00. Following the completion of the transaction, the chief executive officer owned 404,134 shares in the company, valued at approximately $34,351,390. This trade represents a 25.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 229,597 shares of company stock valued at $19,646,746. Insiders own 3.08% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CBT. Hohimer Wealth Management LLC increased its position in shares of Cabot by 6.3% during the 3rd quarter. Hohimer Wealth Management LLC now owns 2,944 shares of the specialty chemicals company's stock valued at $226,000 after purchasing an additional 174 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Cabot by 7.6% in the 3rd quarter. Parallel Advisors LLC now owns 2,484 shares of the specialty chemicals company's stock worth $191,000 after buying an additional 176 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Cabot in the 3rd quarter worth about $481,000. Signaturefd LLC grew its position in Cabot by 43.6% during the third quarter. Signaturefd LLC now owns 1,954 shares of the specialty chemicals company's stock valued at $150,000 after buying an additional 593 shares during the period. Finally, Sterling Capital Management LLC grew its position in Cabot by 117.5% during the third quarter. Sterling Capital Management LLC now owns 6,954 shares of the specialty chemicals company's stock valued at $535,000 after buying an additional 3,757 shares during the period. Institutional investors and hedge funds own 93.18% of the company's stock.

Cabot News Roundup

Here are the key news stories impacting Cabot this week:

• Positive Sentiment: Fourth-quarter adjusted EPS was $1.61, above the $1.55 consensus, while revenue rose 12.2% year over year to $1.01 billion, exceeding estimates. Cabot beats Q4 earnings and revenue estimates
• Positive Sentiment: Battery Materials generated $43 million of full-year EBITDA, and Cabot secured a $50 million Department of Energy grant to expand U.S. production of battery conductive additives—potential support for longer-term growth. Cabot reports fourth-quarter and fiscal-year results
• Neutral Sentiment: The company plans $200 million to $230 million in fiscal 2027 capital spending. That investment could support growth, although it represents a substantial use of cash. Cabot forecasts fiscal 2027 EPS and capital spending
• Negative Sentiment: Fiscal 2027 adjusted EPS guidance of $6.15–$6.75 is below the $7.03 analyst consensus, signaling expectations for softer earnings ahead. Cabot forecasts fiscal 2027 EPS
• Negative Sentiment: Despite the quarterly beat, adjusted EPS declined from $1.70 a year earlier; full-year adjusted EPS fell to $6.42 from $7.25. Reports also pointed to weaker margins, tempering the strong revenue growth. Cabot falls despite beating estimates on weaker margins

About Cabot

Cabot Corporation NYSE: CBT is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company develops and manufactures materials used to improve the performance, durability, conductivity, color and purity of products across a range of industries.

Cabot's products include carbon black used in tires, rubber goods, coatings, plastics and printing inks; specialty carbons and conductive materials for batteries and other applications; and specialty compounds and masterbatches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.